Skip to content

Study · Non-randomized trial · 2000

2 results

[Immunomodulating activity of thymogen in acute pancreatitis].

Saĭdakhmedova ZT

Voprosy pitaniia1 Jan 2000

PMID11452372 (opens in a new tab)PepBankPUB-11452372
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with acute pancreatitis, thymogen added to complex treatment was associated with positive clinical changes.

    In plain wordsIn patients with acute pancreatitis, thymogen added to treatment was linked to improved clinical changes.

    Peptide
    Thymogen (oglufanide)
    Outcome
    Direction not reportedClinical changes
    Study

    n: not reported in source

    Outcome group
    Overall treatment effect · Gastrointestinal
    Studied dose
    0.5-0.8 mg per treatment courseAs given in this study (human).

    Source sentences

    Summary
    Including of tymogen in complex treatment at the dose 0.5-0.8 mg for the treatment course at AP diseased was having immune correcting action and leadind to positive dynamics of clinical changes.
    1 context sentence
    Summary · context
    Immunity system parameters were explored at 48 persons with diagnosis of acute pancreatitis (AP) and at 36 practically healthy persons (donors).
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with acute pancreatitis treated with thymogen, T-cell immune deficiency was eliminated.

    In plain wordsIn patients with acute pancreatitis, thymogen treatment was linked to elimination of T-cell immune deficiency.

    Peptide
    Thymogen (oglufanide)
    Outcome
    DecreaseT-cell immune deficiency
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    0.5-0.8 mg per treatment courseAs given in this study (human).

    Source sentences

    Summary
    It was observed elimination of T-cell immune deficiency at AP diseased.
    2 context sentences
    Summary · context
    Including of tymogen in complex treatment at the dose 0.5-0.8 mg for the treatment course at AP diseased was having immune correcting action and leadind to positive dynamics of clinical changes.
    Summary · context
    Immunity system parameters were explored at 48 persons with diagnosis of acute pancreatitis (AP) and at 36 practically healthy persons (donors).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.